Metabolic Management in Midlife Determines the Future of Cognitive Function: Controlling Chronic Inflammation and Long-term Intervention Strategies

The Strategic Importance of 'Integrated Brain-Metabolic Management' in MidlifeFrom the perspective of the latest preventive ...

What are Hormones? The Mechanism of Controlling the Human Body with 'Chemical Signals'

The mechanism of controlling the human body with 'chemical signals'What I found interesting while researching hormones is ...
PR Newswire

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

PRNewswire/ -- (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results ...

Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment compar…

Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing ...
PR Newswire

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new …

PRNewswire/ -- (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that ...
MarketScreener

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

PRINCETON - Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ('MCR') system, reported financial results for the fiscal ...
Latrobe Bulletin NewsOpinion

Savvy Senior | Planning a simple, affordable funeral

Journalist and senior advocate Jim Miller is the creator of Savvy Senior, a weekly information column devoted to older adults ...